Increased β1 integrin is associated with decreased survival in invasive breast cancer

Cancer Research

Volumn 67, Issue 2, 2007, Pages 659-664

  Yao, Evelyn S ^a   Zhang, Hui ^d   Chen, Yunn Yi ^b   Lee, Brian ^a   Chew, Karen ^c   Moore, Dan ^a   Park, Catherine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; FIBRONECTIN; LAMININ 1; LAMININ;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTRACELLULAR MATRIX; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MICROENVIRONMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; XENOGRAFT; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; EXTRACELLULAR FLUID; IMMUNOHISTOCHEMISTRY; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; SURVIVAL RATE;

ANTIGENS, CD29; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EXTRACELLULAR FLUID; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 33846653542     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2768     Document Type: Article

References (41)

1. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002;70:537-46.
2. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005;5:51-63.
3. Boudreau N, Werb Z, Bissell MJ. Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. Proc Natl Acad Sci U S A 1996;93:3509-13.
4. Wang F, Hansen RK, Radisky D, et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 2002;94:1494-503.
5. Weaver VM, Petersen OW, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:231-45.
6. 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci U S A 1995;92:7411-5.
7. 1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004;6:159-70.
8. 1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 2006;66:1526-35.
9. Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2002;2:37-43.
10. 1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
11. Cordes N, Beinke C. Fibronectin alters cell survival and intracellular signaling of confluent A549 cultures after irradiation. Cancer Biol Ther 2004;3:47-53.
12. Cordes N, Beinke C, Plasswilm L, van Beuningen D. Irradiation and various cytotoxic drugs enhance tyrosine phosphorylation and β(1)-integrin clustering in human A549 lung cancer cells in a substratum-dependent manner in vitro. Strahlenther Onkol 2004;180:157-64.
13. Muschler J, Levy D, Boudreau R, Henry M, Campbell K, Bissell MJ. A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. Cancer Res 2002;62:7102-9.
14. Singh J, Itahana Y, Knight-Krajewski S, et al. Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res 2004;64:6152-9.
15. Viacava P, Naccarato AG, Collecchi P, Menard S, Castronovo V, Bevilacqua G. The spectrum of 67-kD laminin receptor expression in breast carcinoma progression. J Pathol 1997;182:36-44.
16. Molino A, Pedersini R, Micciolo R, et al. Prognostic significance of laminin, laminin receptor, and bone marrow micrometastases in breast cancer patients: are these markers of aggressive behavior and metastatic potential? Appl Immunohistochem Mol Morphol 2003;11:311-8.
17. Ioachim E, Charchanti A, Briasoulis E, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV, and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002;38:2362-70.
18. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
19. 1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol 2004;27:215-9.
20. Bottger TC, Maschek H, Lobo M, Gottwohl RG, Brenner W, Junginger T. Prognostic value of immunohistochemical expression of β-1 integral in pancreatic carcinoma. Oncology 1999;56:308-13.
21. v as prognostic factors in human metastatic melanoma. Melanoma Res 2004;14:29-37.
22. Jonjic N, Lucin K, Krstulja M, Iternicka Z, Mustac E. Expression of β-1 integrals on tumor cells of invasive ductal breast carcinoma. Pathol Res Pract 1993;189:979-84.
23. Gui GP, Wells CA, Browne PD, et al. Integrin expression in primary breast cancer and its relation to axillary nodal status. Surgery 1995;117:102-8.
24. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
25. 4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002;2:205-16.
26. 1-integrins in invasive breast cancer. J Pathol 1999;187:523-9.
27. 1 integrin expression with histological type and hormonal receptor status in breast carcinomas. Pathol Res Pract 1996;192:1031-8.
28. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 1992;23:1159-66.
29. 1 integrins in non-neoplastic mammary epithelium, fibroadenoma, and carcinoma of the breast. Virchows Arch A Pathol Anat Hist 1993;422:203-10.
30. 1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci U S A 1998;95:14821-6.
31. Elliott BE, Maxwell L, Arnold M, Wei WZ, Miller FR. Expression of epithelial-like markers and class I major histocompatibility antigens by a murine carcinoma growing in the mammary gland and in metastases: orthotopic site effects. Cancer Res 1988;48:7237-45.
32. 1 subunit antibody. Jpn J Cancer Res 1992;83:1317-26.
33. 1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res 2002;22:1065-70.
34. Jia Y, Zeng ZZ, Markwart SM, et al. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res 2004;64:8674-81.
35. Juarez JC, Guan X, Shipulina NV, et al. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res 2002;62:5344-50.
36. Shannon KE, Keene JL, Settle SL, et al. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin Exp Metastasis 2004;21:129-38.
37. 1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;104:496-503.
38. 1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 2006;25:1378-90.
39. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001;20:4995-5004.
40. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000;38:71-81.
41. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation. Leukemia 2001;15:1232-9.